Neurocrine Biosciences (NBIX) Interest Expenses (2011 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Interest Expenses of $583.1 million for Q2 2026, up 6369.89% year-over-year from $9.0 million in Q2 2025, and down 1.2% on a QoQ basis from $590.2 million in Q1 2026.
Neurocrine Biosciences (NBIX) Interest Expenses (2011 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Interest Expenses for 15 years, with the latest figure at $583.1 million in Q2 2026.
- Interest Expenses for Q2 2026 came in at $583.1 million, up 6369.89% year-over-year; the trailing twelve-month figure through Jun 2026 was $583.1 million (up 1830.79% YoY), and the FY2025 annual result was $97.3 million, down 13.28% from the prior year.
- Interest Expenses retreated to $583.1 million in Q2 2026, from $590.2 million in the prior quarter.
- Over five years, Interest Expenses peaked at $619.5 million in Q3 2025 and troughed at -$9.3 million in Q2 2025.
- A 5-year average of $160.6 million and a median of $15.2 million in 2023 frame the typical range for Interest Expenses.
- The widest annual swing landed in 2023, when Interest Expenses jumped 10408.33%; it then plunged 102.44% in 2025.
- A 5-year view of Interest Expenses shows it stood at $10.9 million in 2022, then tumbled by 82.57% to $1.9 million in 2023, then soared by 1557.89% to $31.5 million in 2024, then sank by 69.52% to $9.6 million in 2025, then jumped by 5973.96% to $583.1 million in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $583.1 million in Q2 2026, $590.2 million in Q1 2026, and $9.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | -400.56 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 2.90 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 120.70 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 2.90 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 59.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 25.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 583.10 Mn |
| Jun 30, 2026 | 583.10 Mn |
| Mar 31, 2026 | 590.20 Mn |
| Mar 31, 2026 | 590.20 Mn |
| Dec 31, 2025 | -28.20 Mn |
| Dec 31, 2025 | -28.20 Mn |
| Sep 30, 2025 | 619.50 Mn |
| Sep 30, 2025 | 619.50 Mn |
| Jun 30, 2025 | 636.50 Mn |
| Jun 30, 2025 | 636.50 Mn |
| Mar 31, 2025 | 9.30 Mn |
| Mar 31, 2025 | 9.30 Mn |
| Dec 31, 2024 | -22.40 Mn |
| Dec 31, 2024 | -22.40 Mn |
| Sep 30, 2024 | 35.80 Mn |
| Sep 30, 2024 | 35.80 Mn |
| Jun 30, 2024 | 381.00 Mn |
| Jun 30, 2024 | 381.00 Mn |
| Mar 31, 2024 | 6.10 Mn |
| Mar 31, 2024 | 6.10 Mn |